What is the maximum recommended daily dose of fluoxetine?

Maximum Recommended Dose of Fluoxetine

The maximum recommended daily dose of fluoxetine is 80 mg/day across all FDA-approved indications, including major depressive disorder, obsessive-compulsive disorder, panic disorder, and bulimia nervosa. 1

FDA-Approved Dosing by Indication

Major Depressive Disorder

• For adults, the initial dose is 20 mg/day administered in the morning, which is sufficient to obtain a satisfactory response in most cases 1
• Doses above 20 mg/day may be administered once daily (morning) or twice daily (morning and noon), with a maximum of 80 mg/day 1
• For pediatric patients (children and adolescents), treatment should be initiated with 10 or 20 mg/day, with a target dose of 20 mg/day after 1 week for those starting at 10 mg/day 1
• In lower-weight children, the starting and target dose may be 10 mg/day, with a possible increase to 20 mg/day after several weeks if needed 1

Obsessive-Compulsive Disorder

• For adults, the initial dose is 20 mg/day in the morning 1
• A dose range of 20 to 60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD 1
• The maximum fluoxetine dose should not exceed 80 mg/day 1
• For adolescents and higher-weight children, treatment should be initiated at 10 mg/day, increased to 20 mg/day after 2 weeks, with a recommended dose range of 20 to 60 mg/day 1
• For lower-weight children, initiate at 10 mg/day with a recommended dose range of 20 to 30 mg/day 1

Bulimia Nervosa

• The recommended dose is 60 mg/day, administered in the morning, as only this dose was statistically significantly superior to placebo in reducing binge-eating and vomiting 1
• For some patients, it may be advisable to titrate up to this target dose over several days 1
• Fluoxetine doses above 60 mg/day have not been systematically studied in patients with bulimia 1

Panic Disorder

• Fluoxetine at 20 mg daily is safe and efficacious in reducing symptoms of panic disorder 2
• Patients who fail to obtain a satisfactory response at 20 mg daily may benefit from dose increases up to a maximum of 60 mg daily 2

Dose-Related Adverse Events

• At 20 mg/day, only nausea and insomnia were reported by a significantly greater percentage of patients compared to placebo 3
• At 60 mg/day, nausea, anxiety, dizziness, and insomnia were reported by a significantly greater percentage of patients compared to placebo 3
• The frequency of side effects is low and dose-related; the most common effects are nausea, anxiety, insomnia, anorexia, diarrhea, nervousness, and headache 4
• Higher doses (above 20 mg/day) are associated with more common adverse events 5

Special Population Considerations

Hepatic Impairment

• A lower or less frequent dosage should be used in patients with hepatic impairment 1
• The elimination half-life of fluoxetine was prolonged in cirrhotic patients (mean of 7.6 days compared to 2-3 days in subjects without liver disease), and norfluoxetine elimination was also delayed (mean of 12 days versus 7-9 days in normal subjects) 1

Renal Impairment

• Dosage adjustments for renal impairment are not routinely necessary 1
• In depressed patients on dialysis receiving 20 mg once daily for 2 months, steady-state fluoxetine and norfluoxetine plasma concentrations were comparable to those in patients with normal renal function 1

Elderly Patients

• A lower or less frequent dosage should be considered for elderly patients 1
• Combined fluoxetine plus norfluoxetine plasma concentrations in elderly patients (≥60 years) receiving 20 mg for 6 weeks were 209.3 ± 85.7 ng/mL, with no unusual age-associated pattern of adverse events 1

Pharmacokinetic Considerations

• Fluoxetine has a long elimination half-life of 1-3 days after acute administration and 4-6 days after chronic administration 1
• The active metabolite norfluoxetine has an elimination half-life of 4-16 days after acute and chronic administration 1
• After 30 days of dosing at 40 mg/day, plasma concentrations of fluoxetine ranged from 91 to 302 ng/mL and norfluoxetine from 72 to 258 ng/mL 1
• The long elimination half-lives ensure that active drug substance will persist in the body for weeks after dosing is stopped, primarily depending on individual patient characteristics, previous dosing regimen, and length of previous therapy 1

Clinical Efficacy at Different Doses

• Studies comparing fluoxetine 20,40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major depressive disorder in most cases 1
• In one OCD study, no dose-response relationship for effectiveness was demonstrated, though a second study suggested a possible dose-response relationship 1
• The full therapeutic effect may be delayed until 5 weeks of treatment or longer 1
• For patients who fail to respond to 20 mg/day after 8-12 weeks, increasing to 60 or 80 mg/day resulted in significant decreases in HAM-D-17 and CGIS scores after 4 weeks, with no significant side effects noted 6

Critical Safety Warnings

• At least 14 days should elapse between discontinuation of an MAOI and initiation of fluoxetine 1
• At least 5 weeks, perhaps longer, should be allowed after stopping fluoxetine before starting an MAOI due to the long elimination half-life 1
• Fluoxetine is an inhibitor of cytochrome P450 2D6 and other CYP enzymes, which increases the potential for drug interactions 5